These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 16093464

  • 21. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U, Gertz B.
    Proc Assoc Am Physicians; 1996 May; 108(3):230-8. PubMed ID: 8774056
    [Abstract] [Full Text] [Related]

  • 22. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH.
    N Engl J Med; 2001 May 10; 344(19):1434-41. PubMed ID: 11346808
    [Abstract] [Full Text] [Related]

  • 23. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
    Adis International Ltd.
    Drugs R D; 2003 May 10; 4(4):231-5. PubMed ID: 12848587
    [Abstract] [Full Text] [Related]

  • 24. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 10; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 25. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB, Treatment of Osteoporosis with Parathyroid Hormone Study Group.
    Ann Intern Med; 2007 Mar 06; 146(5):326-39. PubMed ID: 17339618
    [Abstract] [Full Text] [Related]

  • 26. Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial.
    Greenspan SL, Resnick NM, Parker RA.
    J Clin Endocrinol Metab; 2005 May 06; 90(5):2762-7. PubMed ID: 15713726
    [Abstract] [Full Text] [Related]

  • 27. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
    Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB.
    J Clin Endocrinol Metab; 2002 Oct 06; 87(10):4528-35. PubMed ID: 12364430
    [Abstract] [Full Text] [Related]

  • 28. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D.
    J Clin Endocrinol Metab; 1997 Feb 06; 82(2):620-8. PubMed ID: 9024265
    [Abstract] [Full Text] [Related]

  • 29. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 06; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 30. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
    Ozdemir F, Rodoplu M.
    Chin Med J (Engl); 2005 Mar 05; 118(5):383-90. PubMed ID: 15780207
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Parathyroid and bone. Role of parathyroid hormone in the treatment of osteoporosis].
    Nakamura T.
    Clin Calcium; 2007 Dec 05; 17(12):1823-9. PubMed ID: 18057656
    [Abstract] [Full Text] [Related]

  • 34. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May 05; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 35. Combination and sequential therapy for osteoporosis.
    Heaney RP, Recker RR.
    N Engl J Med; 2005 Aug 11; 353(6):624-5. PubMed ID: 16093472
    [No Abstract] [Full Text] [Related]

  • 36. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
    Greenspan SL, Beck TJ, Resnick NM, Bhattacharya R, Parker RA.
    J Bone Miner Res; 2005 Sep 11; 20(9):1525-32. PubMed ID: 16059624
    [Abstract] [Full Text] [Related]

  • 37. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 11; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 38. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
    Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D.
    N Engl J Med; 2004 Feb 19; 350(8):767-76. PubMed ID: 14973216
    [Abstract] [Full Text] [Related]

  • 39. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 40. Alendronate for the treatment of osteoporosis in men.
    Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A.
    N Engl J Med; 2000 Aug 31; 343(9):604-10. PubMed ID: 10979796
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.